Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection.
Oral miltefosine was administered to 39 human immunodeficiency virus (HIV)-infected patients with leishmaniasis for whom standard leishmaniasis treatment had failed. Initial response was achieved in 25 patients (64%), including 16 patients (43%) with initial parasitological cure. Repeated responses after relapse and tolerability of long courses of treatment indicate the potential for development of optimized dosage schemes.
Sindermann
Herbert
H
Medical Research and Development, Zentaris GmbH, Frankfurt am Main, Germany. herbert.sindermann@zentaris.com
Engel
Kirsten R
KR
Fischer
Christina
C
Bommer
Wolfgang
W
D000284:Administration, Oral; D000328:Adult; D000981:Antiprotozoal Agents / Q000008:administration & dosage*; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D016867:Immunocompromised Host; D007896:Leishmaniasis / Q000188:drug therapy* / Q000209:etiology* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010767:Phosphorylcholine / Q000008:administration & dosage / Q000031:analogs & derivatives*
D000981:Antiprotozoal Agents; D010767:Phosphorylcholine; C039128:miltefosine